Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from AC Immune SA ( (ACIU) ) is now available.
AC Immune reported its full-year 2025 results on March 13, 2026, highlighting positive interim Phase 2 data for its wholly owned active immunotherapy ACI-7104, which appeared to slow progression in early Parkinson’s disease and showed a favorable safety and immunogenicity profile. The company also initiated a Phase 1 trial of its brain-penetrant NLRP3 inhibitor ACI-19764, advanced Morphomer Tau aggregation inhibitors toward IND-enabling studies, and outlined multiple 2026 clinical milestones across its Alzheimer’s, Parkinson’s and small-molecule programs.
Management conducted a strategic review that sharpened focus on its highest-priority assets, including three clinical-stage active immunotherapies and key small-molecule programs, while cutting its workforce by about 30% to extend its cash runway. AC Immune ended 2025 with CHF 91.4 million in cash resources, down from CHF 165.5 million a year earlier, but expects funding to last into the third quarter of 2027, as lower R&D and G&A spending and targeted restructuring position the company for upcoming value-inflection data readouts despite a sharp decline in contract revenues after a large 2024 milestone payment.
The most recent analyst rating on (ACIU) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
The score is held down primarily by weak financial performance (sharp TTM revenue decline, persistent losses, and renewed cash burn) and a loss-making valuation profile (negative P/E, no dividend yield). These are partially offset by a solid balance-sheet leverage position and supportive technicals with price above key moving averages and positive MACD.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a Lausanne, Switzerland-based, clinical-stage biopharmaceutical company focused on precision therapeutics and diagnostics for neurodegenerative diseases. Its pipeline centers on active immunotherapies and small-molecule drugs targeting pathological proteins such as α-synuclein, Tau, Abeta and NLRP3, with programs in Parkinson’s and Alzheimer’s disease and broader inflammatory and neurodegenerative indications.
Average Trading Volume: 365,121
Technical Sentiment Signal: Hold
Current Market Cap: $296.8M
Find detailed analytics on ACIU stock on TipRanks’ Stock Analysis page.